MonTa Biosciences is a Clinical Stage Biotech Company with a vision to develop better cancer treatment for patients by utilizing the immune system to recognize and kill tumor cells – ultimately building an immune memory response that will protect the patient from metastatic disease.

MonTa Biosciences is advancing MBS8, a second-generation systemic TLR7 agonist designed to turn “Cold” tumors “Hot” and restore response to immunotherapy in checkpoint resistant cancers.

Our expansion phase study is currently ongoing at sites in Denmark and Spain in two indications:

  • Cutaneous Melanoma with secondary resistance to checkpoint therapy

  • Uveal Melanoma with secondary resistance to immunotherapy

Read more about our study here Study Link 

 

RECENT NEWS

First patient treated in Cutaneous Melanoma patient with secondary resistance
June 10, 2026

Today marks a major milestone for MonTa Biosciences: the first patient has been dosed in [...]

Read more
Meet us at BioEquity in Praha in early May
May 1, 2026

MonTa Biosciences will be joining the BioEquity meeting in Praha in early May to build [...]

Read more
MonTa Biosciences Initiates Expansion Phase with Systemic TLR7 Agonist MBS8 in Checkpoint-Resistant Melanoma Amid Renewed Momentum in the TLR7 Field
February 27, 2026

Please find our Press Release here: Press Release Feb 2026 MonTa initiates expansion clinical study

Read more
MonTa Biosciences announce submission of clinical protocol for expansion phase
December 10, 2025

MonTa Biosciences announces submission of clinical protocol to expand treatment of our second generation TLR7 [...]

Read more